Chinese Researchers Achieve Global First: RNA Editing Technology LEAPER Enters Clinical Trials for Duchenne Muscular Dystrophy
Key Insights
A Chinese team has published the first-ever clinical application of RNA editing for Duchenne muscular dystrophy (search) (DMD) in the journal Cell, marking a global milestone.
The novel LEAPER (search) technology uses engineered RNA molecules to harness endogenous human enzymes for precise gene correction, avoiding the need for exogenous editing enzymes.
Three pediatric patients treated with LEAPER (search)-based candidate drugs demonstrated significant and sustained motor function improvements over a one-year follow-up period.
A Chinese research team has achieved a landmark breakthrough in gene therapy, publishing the first-ever clinical application of RNA editing technology for the treatment of Duchenne muscular dystrophy (search) (DMD). The findings, detailing both the LEAPER (search) (Leveraging Endogenous ADAR for Programmable Editing of RNA) technology and its clinical application, were published on Wednesday in the journal Cell.
This represents the first time a China-developed RNA editing technology has entered clinical trials, and the first time globally that RNA editing has been applied in DMD treatment.
The Unmet Need in DMD
DMD is a severe and rare hereditary disease caused by gene mutations, characterized by progressive muscle atrophy and loss of motor function. Patients typically develop symptoms in childhood, gradually lose the ability to walk, and most die prematurely from respiratory or heart failure. Although classified as a rare disease, China has one of the world's largest DMD patient populations due to its vast population base. Current treatments can only partially delay disease progression but cannot reverse the course of the illness.
The disease is widely recognized as one of the most challenging targets in gene therapy. Its causative gene is too large for conventional gene therapy methods to deliver the complete gene into patients' bodies. Furthermore, different patients carry more than 7,000 types of pathogenic mutations, meaning a single treatment regimen can often only cover a small fraction of patients. Developing treatment strategies that combine broad applicability with long-term efficacy has remained a major challenge for the global medical community.
How LEAPER (search) Works
The new RNA editing technology was developed by a team from the Beijing-based Changping Laboratory (search) and Peking University (search). According to team leader Wei Wensheng, LEAPER (search) system components can precisely locate the erroneous genetic "blueprint" in muscle cells, restore the gene by removing specific sequences, and enable cells to produce functional proteins according to the corrected "blueprint," helping muscles regain vitality.
Unlike traditional gene-editing approaches, LEAPER (search) does not require delivery of exogenous editing enzymes. Using only a segment of engineered RNA molecules, it can mobilize key enzymes that naturally exist in human cells to achieve precise editing of target RNA. The system is notably simple, with high safety and minimal delivery burden compared to conventional methods.
Clinical Results and Collaboration
The team collaborated with Kunming University of Science and Technology (search), Shanghai Jiao Tong University (search), and other institutions to develop candidate drugs based on the LEAPER (search) platform. Three pediatric patients who received treatment all demonstrated significant and sustained improvements in motor function during the one-year follow-up period.
Xie Xiaoliang, director of Changping Laboratory (search) and an academician of the Chinese Academy of Sciences, stated that the development and application of the LEAPER (search) platform reflects the laboratory's commitment to developing new drugs through original basic research and cutting-edge technology. He expressed hope that this new technology would benefit more patients suffering from major diseases.